Tanideh N, Rokhsari P, Mehrabani D, et al. The healing effect of licorice on Pseudomonas aeruginosa infected burn wounds in experimental rat model[J]. World J Plast Surg, 2014, 3（2）：99-106.
[2]
Sugawara E, Nagano K, Nikaido H. Alternative folding pathways of the major porin OprF of Pseudomonas aeruginosa[J]. FEBS J, 2012, 279（6）：910-918.
[3]
Peluso L, de Luca C, Bozza S, et al. Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization[J]. BMC Microbiol, 2010, 10（9）：1741-1752.
[4]
Krause A, Whu WZ, Qiu J, et al. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF[J]. Clin Exp Immunol, 2013, 173（2）：230-241.
Stryjewska A, Kiepura K, Librowski T, et al. Biotechnology and genetic engineering in the new drug development Part II monoclonal antibodies, modern vaccines and gene therapy[J]. Pharmacological Reports, 2013, 65（5）：1086-1101.
Zhu X, Ma Z, Wang J, et al. Importance of tryptophan in transforming an amphipathic peptide into a Pseudomonas aeruginosa-targeted antimicrobial peptide[J]. PLoS One, 2014, 9（12）：e114605.
Krause A, Whu WZ, Xu Y, et al. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF[J]. Vaccine, 2011, 29（11）：2131-2139.
[14]
Ding B, von Specht BU, Li Y. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa[J]. Vaccine, 2010, 28（25）：4119-4122.
Westritschnig K, Hochreiter R, Wallner G, et al. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine（IC43）in healthy volunteers[J]. Hum Vaccin Immunother, 2014, 10（1）：170-183.
[18]
Zhang L, Cai D, Zhao X, et al. Liposomes containing recombinant gp85 protein vaccine against ALV-J in chickens[J]. Vaccine, 2014, 32（21）：2452-2456.
